BACE2 and Alzheimer disease: Among BACE2-related enrichments surviving FDR multiple testing correction, we observed: Alzheimer’s disease (AD, KEGG hsa05010, FDR q = 2.2 × 10–4) related to the interaction of BACE2 with APP and BACE1; membrane protein ectodomain proteolysis (GO: 0006509, FDR q = 0.007) and amyloid-beta metabolic process (GO: 0050435, FDR q = 0.007) related to BACE2-BACE1 interaction; protein metabolic process (GO: 0019538, FDR q = 0.043) related to the interaction of BACE with APP, BACE1, FYN, and IGHV3-11.